$3.07 Million in Sales Expected for KemPharm, Inc. (NASDAQ:KMPH) This Quarter

Wall Street analysts forecast that KemPharm, Inc. (NASDAQ:KMPHGet Rating) will announce sales of $3.07 million for the current quarter, Zacks reports. Two analysts have provided estimates for KemPharm’s earnings, with the highest sales estimate coming in at $4.13 million and the lowest estimate coming in at $2.00 million. KemPharm posted sales of $12.12 million in the same quarter last year, which suggests a negative year-over-year growth rate of 74.7%. The company is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that KemPharm will report full-year sales of $20.82 million for the current financial year, with estimates ranging from $16.22 million to $25.42 million. For the next year, analysts forecast that the firm will post sales of $47.86 million, with estimates ranging from $25.97 million to $69.76 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover KemPharm.

KemPharm (NASDAQ:KMPHGet Rating) last released its quarterly earnings results on Wednesday, March 30th. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.08). KemPharm had a positive return on equity of 7.03% and a negative net margin of 29.86%.

Several analysts have issued reports on the company. Zacks Investment Research downgraded KemPharm from a “hold” rating to a “sell” rating in a research note on Wednesday. StockNews.com assumed coverage on KemPharm in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, HC Wainwright raised KemPharm from a “neutral” rating to a “buy” rating and increased their price target for the company from $10.00 to $11.00 in a research report on Monday, January 31st.

Several large investors have recently added to or reduced their stakes in KMPH. Nisa Investment Advisors LLC bought a new position in shares of KemPharm in the fourth quarter valued at $26,000. Citigroup Inc. boosted its position in KemPharm by 139.5% during the third quarter. Citigroup Inc. now owns 3,257 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 1,897 shares during the period. Advisor Group Holdings Inc. boosted its position in KemPharm by 357.2% during the third quarter. Advisor Group Holdings Inc. now owns 4,535 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 3,543 shares during the period. City State Bank bought a new position in KemPharm during the fourth quarter worth $71,000. Finally, Wells Fargo & Company MN boosted its position in KemPharm by 72.0% during the second quarter. Wells Fargo & Company MN now owns 5,719 shares of the specialty pharmaceutical company’s stock worth $73,000 after purchasing an additional 2,394 shares during the period. 34.09% of the stock is owned by institutional investors and hedge funds.

KMPH opened at $4.23 on Friday. The business’s 50-day moving average price is $5.23 and its two-hundred day moving average price is $7.25. KemPharm has a 1 year low of $4.10 and a 1 year high of $15.70.

KemPharm Company Profile (Get Rating)

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Recommended Stories

Get a free copy of the Zacks research report on KemPharm (KMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.